drugset / Trial / NCT04744402
Phase 2 Clinical Trial of CartiLife® in the United States
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject with articular cartilage defects of the knee as a result of trauma or degeneration.
Timeline
- Start
- 2020-10-28
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CartiLife | Cell therapy | 480 unknown | Other |